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ABSTRACT
Objective: The safety and efficacy of ampicillin plus sulbactam were compared with those of ce-
foxitin in the treatment of women with pelvic inflammatory disease (PID).
Methods: This single-site, randomized, prospective, third-party-blinded, comparative, parallel-
treatment study enrolled 93 women with a diagnosis of PID. Patients were treated with either
ampicillin/sulbactam (2 g/1 g, administered intravenously [IV], every 6 h) or cefoxitin (2 g, admin-
istered IV, every 6 h) for a minimum of 12 doses. Patients with cultures positive for Chlamydia
trachomatis also received concurrent oral or IV doxycycline (100 mg twice daily). Patients with
cultures negative for C. trachomatis received prophylactic oral doxycycline (100 mg twice daily) for
10-14 days after treatment with either ampicillin/sulbactam or cefoxitin was completed.
Results: Ninety-three patients were entered in the study: 47 in the ampicillin/sulbactam arm and
46 in the cefoxitin arm. All 93 patients were evaluable for safety; 61 (66%) were evaluable for
efficacy. Demographic characteristics were similar for the groups. Of the 27 evaluable ampicillin/
sulbactam-treated patients, 67% experienced clinical cure, 30% improved, and 4% failed treatment.
Respective values for the 34 cefoxitin-treated patients were 68%, 24%, and 9% (P 0.67). Patho-
gens were eradicated in 70% of the women given ampicillin/sulbactam vs. 56% of those who re-
ceived cefoxitin (P 0.64).
Conclusions: Overall, ampicillin/sulbactam demonstrated clinical and bacteriologic efficacy at
least equivalent to that of cefoxitin in the treatment ofwomen with acute PID. The use of ampicillin/
sulbactam for this indication may avoid the complex dosing regimens associated with other treat-
ments. Infect. Dis. Obstet. Gynecol. 5:319-325, 1997. (C) 1998 Wiley-Liss, Inc.
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elvic inflammatory disease (PID) is a common
and serious complication of sexually acquired
infection. From 1979 to 1988, an average of nearly
190,000 women were hospitalized annually for
PID, and nearly 400,000 first visits per year for PID
were made to physicians’ offices. According to
more recent estimates, PID results in approxi-
mately 2.5 million office visits and 267,000 hospi-
talizations each year in the United States alone, z
Serious long-term consequences of PID, includ-
ing chronic pelvic pain, infertility, ectopic preg-
nancy, or major pelvic or abdominal surgery, will
affect one fourth of the women with this infec-
tion.3,4
Although Neisseria gonorrhoeae and Chlamydia
trachomatis are most commonly associated with
PID,4-6 this disease may arise from both aerobic
and anaerobic flora normally present in the lower
genital tract. 7,8 Among causative pathogens are
aerobic organisms such as Escherichia toll, group B
streptococci, and other facultative streptococci, as
well as anaerobic organisms including Prevotella hi-
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vius, other Prevotella species, and peptostrepto-
cocci. 7
The polymicrobial nature of PID requires em-
piric therapy with a broad-spectrum antimicrobial
agent or combination. 8,9 Complicating effective
therapy, however, has been the development of
significant antibiotic resistance8-1 through produc-
tion of penicillinase by N. gonorrhoeae and of 13-
lactamase by various other causative pathogens of
PID.8-1 Although combination therapy with gen-
tamicin and clindamycin has been considered the
"gold standard, ’’8,11 in recent clinical trials9,,1z
the combination of the [3-1actam ampicillin and the
[3-1actamase inhibitor sulbactam has demonstrated
excellent activity against pathogens associated with
pelvic infections in women.1,4
The present study was undertaken to directly
compare the efficacy and safety of ampicillin/
sulbactam and cefoxitin, a semisynthetic cephamy-
tin, in women with PID.
SUBJECTS AND METHODS
Eligible for enrollment were females 14 years of
age or older who provided informed written con-
sent (including parental or legal guardian consent
for patients <18 years of age) and who had a diag-
nosis of PID based on medical history, clinical
laboratory findings, physical examination, and
clinical signs and symptoms of infection, including
abdominal, adnexal, or cervical motion tenderness.
Leukocyte count ->10,000 mm", temperature
-> 100.4 F, left shift (bands -> 10%), or endocervical
discharge positive for gram-negative intraccllular
diplococci were also required. Ultrasonography was
employed, as necessary, to rule out the presence of
abdominal abscess.
Before study initiation, the study protocol and
statement of informed consent were reviewed and
approved by the institutional review committee.
Criteria for exclusion were known hypersensi-
tivity to cephalosporins or penicillins; need for con-
comitant antibiotic therapy; terminal illness with
death likely within 48 h; severe underlying disease
that might interfere with evaluation of the thera-
peutic response; successful antimicrobial therapy
within 4 days prior to study entry; ongoing treat-
ment with another investigational drug; impaired
immunological function or neutropenia (neutrophil
count <1,500 mm3); serum creatinine >1.5 mg/dl;
pregnancy; or known liver disease (liver function
test ->twice normal value).
Patients provided medical and surgical histories
and underwent physical examination. Within 48 h
prior to initiation of therapy, endocervical speci-
mens were taken for aerobic culture of N. gonor-
rhoeae, C. trachomatis, Mycoplasma hominis, and Urea-
plasma urealyticum. Uncontaminated specimens
from normally sterile sites taken during culdocen-
tesis, laparoscopy, or laparotomy were also cultured
for aerobes and anaerobes. Follow-up endocervical
cultures were not required, except to document
treatment failure. Because PID may have a clinical
presentation similar to, or may occur concurrently
with, pyelonephritis, at least 2 blood cultures with
specimens from separate sites were performed to
aid in the differential diagnosis; follow-up cultures
were obtained if bacterial growth was noted. All
probable bacterial pathogens were tested for sus-
ceptibility to ampicillin, ampicillin/sulbactam, and
cefoxitin.
Within 24 h of admission, patients were tested
for C. trachomatis by the immunofluorescent anti-
body test. A positive result was defined as C. tra-
chomatis on either this test or culture.
Pretreatment blood samples were collected for
complete blood count with differential, volume,
and platelet count. Prothrombin time and partial
thromboplastin time were performed in patients
with signs of bleeding disorders. Blood chemistry
profiles included alanine and aspartate aminotrans-
ferases, serum creatinine, and blood urea nitrogen.
Urinalysis was also performed. Pretrcatment and
follow-up radiographic and sonographic procedures
were carried out at the investigator’s discretion.
Patients were randomly assigned to receive ei-
ther ampicillin/sulbactam (2 g/1 g) or cefoxitin (2 g)
both administered intravenously (IV) every 6 h.
Doxycycline, 100 mg twice daily, either oral or IV,
was administered concurrently to patients with cul-
tures positive for C. trachomatis. Because of the sig-
nificant possibility of false negatives, patients with
cultures negative for C. trachomatis were empiri-
cally treated with 10-14 days of oral doxycycline,
100 mg twice daily, after the study ended. A mini-
mum of 12 doses of ampicillin/sulbactam and ce-
foxitin were given.
Based on the clinical judgment of the investiga-
tor, other antibiotics or non-pharmacological inter-
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ventions were administered to treatment failures.
Patients were withdrawn from the study for the
following reasons: obvious therapeutic failure of
the study drug; primary pathogen isolated from an
initial culture, or any subsequent culture taken
during the treatment period, resistant to the study
drug(s) and patient failure to respond to therapy
within 48 h; a significant adverse event (including
significant alteration in laboratory parameters); or
request for withdrawal by the patient or the parent
(guardian) of a minor patient.
An initial clinical evaluation was performed on
the first day of therapy, at least every other day
thereafter, and at the end of study drug treatment.
Signs and symptoms of pelvic infection were evalu-
ated. Temperature was recorded, and the presence
or absence of abdominal abscess was noted.
One week after treatment with study drug
ended, all patients underwent a follow-up assess-
ment. An endocervical specimen was taken at this
time from patients with initial C. trachomatis or N.
gonorrhoeae infection to test for eradication. An ad-
ditional follow-up was carried out 4-6 weeks after
the end of treatment.
Whenever possible, sexual partners of patients
testing positive for sexually transmitted disease
(STD) species were treated. At time of discharge,
patients were instructed by the treating physician
to avoid vaginal sexual exposure before follow-up
visits. The use of condoms was encouraged.
The clinical response to treatment was evalu-
ated as cure: disappearance of presenting signs and
symptoms by the end of therapy and at follow-up;
improvement: partial alleviation of signs and symp-
toms by the end of therapy and at follow-up; fail-
ure: no significant effect on signs and symptoms; or
indeterminate: results not evaluable or not fitting
into one of the other categories.
Bacteriologic response to treatment was defined
as eradication: disappearance of culturable material
or elimination of the principal pathogen(s) at the
end of therapy and at follow-up; partial eradication:
some, but not all, multiple causative pathogens ab-
sent after completion of therapy; eradication/
superinfection: elimination of the principal patho-
gen(s) and emergence of a different organism dur-
ing, or at the end of, therapy and at follow-up;
persistence of the principal pathogen at the end of
therapy and at follow-up; or indeterminate: results
not evaluable or not definable per protocol.
TABLE I. Demographic characteristics of
evaluable patients
Ampicillin/sulbactam Cefoxitin
(N 27) (N 34)
Age (years) 22.0 + 5.25 23.4 + 4.70 0.34
Race
White 4 4 0.73
Black 23 30
Weight (Ib) 130.5 + 24.40 136.3 + 25.04 0.81
Height (in.) 63.8 + 2.34 64.2 + 3.43 0.73
aData are presented as mean + standard deviation.
Demographic characteristics were compared by
means of the Wilcoxon rank-sum and Fisher’s ex-
act tests. The Mantel-Haenszel Xe test was used to
compare clinical and bacteriologic outcomes with
the 2 treatments. Duration of hospitalization for
the 2 groups was compared with the Wilcoxon
rank-sum test.
RESULTS
Of the 93 women who entered the trial, 27 of 47
treated with ampicillin/sulbactam and 34 of 46
given cefoxitin were evaluable for clinical and bac-
teriologic efficacy (Table 1). In both treatment
groups, patients not evaluable were primarily those
lost to follow-up. The demographic characteristics
evaluated were statistically similar between groups
(P > 0.34 for all variables). Seven patients in the
ampicillin/sulbactam group and 4 in the cefoxitin
group had documented abdominal abscesses.
Reasons for exclusion from efficacy analyses
(Table 2) were failure to receive the minimum
number of doses (11 ampicillin/sulbactam vs. 3 ce-
foxitin), concomitant antibiotic therapy (3 vs. 4),
administration of doxycycline outside the treat-
ment window (3 vs. 0), positive results on test for
human immunodeficiency virus (HIV) (1 vs. 3),
failure to confirm the initial diagnosis of PID (1 vs.
2), and age <14 years (1 vs. 0). Concomitant anti-
biotics were administered due either to failure of
study medication or to nursing error.
No significant difference in clinical efficacy was
noted between the 2 treatments (P 0.67) (Fig. 1).
Of the 27 evaluable patients who received ampi-
cillin/sulbactam, 67% (N 18) were cured and 30%
(N 8) were improved; treatment failed in 4% (N
1). Respective values for the 34 evaluable pa-
tients treated with cefoxitin were 68% (N 23),
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TABLE 2. Number of patients excluded from
standard efficacy analysis
Reason for
non-evaluability Ampicillin/sulbactam Cefoxitin
Received fewer than the
minimum number of
total doses of study
medication II 3
Received concomitant
antibiotic 3 4
Doxycycline
administered outside
of treatment window 3 0
Diagnosis of PID was not
confirmed 2
Tested positive for HIV 3
Patient’s age was below
minimum age
allowable for study
participation 0
Total 20 12
100/
80
70
67 68
Percentage 60-
of Patients
40-
30-
20-
10-
0
30
24
Cured Improved Failed
)iiii))!i)!i (N=27)Ampicillin/Sulbamam m
Fig. I.
foxitin.
Totals 101% for both drugs because of rounding.
Clinical responses to ampicillin/sulbactam and ce-
24% (N 8), and 9% (N 3). In both treatment
groups, most patients who were clinically improved
required antibiotic therapy that continued post-
study. None required surgical intervention.
Primary pathogens isolated in each treatment
group are detailed in Table 3. Overall, ampicillin/
sulbactam eradicated a higher percentage of caus-
ative pathogens than cefoxitin, although the differ-
ence was not statistically significant (P 0.64) (Fig.
2). Pathogens were eradicated in 70% (N 19) of
evaluable patients treated with ampicillin/sulbac-
tam. Eradication followed by superinfection oc-
curred in 7% (N 2), persistence in 4% (N 1),
and 19% (N 5) had an indeterminate response.
Patients with indeterminate responses were pri-
TABLE 3. Primary bacterial isolates in evaluable
patients by treatment group
Ampicillin/sulbactam Cefoxitin
(N 108 isolates) (N II 5 isolates)
Neisseria gonorrhoeae 38 36
Mycoplasma hominis 36 36
Ureaplasma urealyticum 17 25
Chlamydia trachomatis 13 II
Other 4 7
100
90
8o
7o
7o
Percentage 60 56
of Patients 50
40
30
20
10
0
26
Eradication/ Partial
Eradication Superinfection Eradication Persistence Indeterminate
I)))))))))!)! (N=27)Ampicillin/Sulbactam m
Fig. 2. Bacteriologic responses to ampicillin/sulbactam
and cefoxitin.
marily those for whom no adequate post-therapy
culture was obtained or to whom other IV antibi-
otics were being administered at study entry. Val-
ues for cefoxitin-treated patients were 56% (N
19), 9% (N 3), 3% (N 1), and 26% (N 9). Two
patients (6%) in this group experienced partial
eradication of causative pathogens.
Organisms responsible for superinfection were
3/1. horninis and C. trachomatis in patients receiv-
ing ampicillin/sulbactam, and N. gonorrhoeae and
3/1. hominis in patients treated with cefoxitin. Inde-
terminate responses were primarily due to the
absence of post-therapy culture results and the ad-
ministration of IV antibiotics prior to study entry.
In only 2 of the 13 patients with documented C.
trachomatis infection in the ampicillin/sulbactam
treatment group did infection persist post-treat-
ment. Infection persisted post-treatment in none of
the 11 patients in the cefoxitin treatment group
with documented C. trachomatis infection.
The average (mean ___
standard deviation) dura-
tion of hospitalization was 4.96 ___
0.94 days for the
patients treated with ampicillin/sulbactam and 5 +_
1.73 days for the patients who received cefoxitin
(P 0.85). In both groups, duration of hospitaliza-
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tion was slightly longer (1-2 days) in most treat-
ment failures.
All patients who received study medication
were included in an intent-to-treat analysis.
In the intent-to-treat analysis, 19/47 (40%)of
ampicillin/sulbactam-treatcd patients were cured,
8/47 (17%) improved, 1/47 (2%) failed, and 19/47
(40%) had indeterminate results. In the cefoxitin
treatment group, 23/46 (50%) were cured, 8/46
(17%) improved, 3/46 (7%) failed, and 1.2/46 (26%)
had indeterminate results. There was no statisti-
cally significant difference between treatment
groups for clinical outcome (P 0.40, Mantel-
Haenszel Xz test).
Pathogens were eradicated in 20/47 (43%) of
ampicillin/sulbactam-treated patients. Eradication
followed by superinfection occurred in 2,/47 (4%),
partial eradication in 0/47 (0%), persistence in 1/47
(1%), and in 24/47 (51%), bacteriologic response
was considered indeterminate. In the cefoxitin-
treated group, eradication occurred in 19/46 (41%),
eradication followed by superinfection in 3/46
(7%), partial eradication in 2/46 (4%), and persis-
tence in 1/46 (2%). In 21/46 (46%), the bacteriolog-
ic response was considered indeterminate. There
was no statistically significant difference between
the treatment groups (P 0.67, Mantel-Haenszel
z test).
In the intent-to-treat analysis, the mean dura-
tions of hospitalization for the ampicillin/sulbactam
and cefoxitin groups were 4.87 ___
1.28 and 4.89 ___
1.64 days, respectively (P 0.72, Wilcoxon rank-
sum test).
Adverse events were reported in 56% (N 25)
of 47 patients who received ampicillin/sulbactam
and 61% (N 28) of 46 patients treated with ce-
foxitin. The most common events were vaginal
yeast infection (28% of ampicillin/sulbactam-
treated patients vs. 17% of cefoxitin-treated pa-
tients), constipation (11% vs. 7%), and nausea/
vomiting (4% vs. 11%) (Table 4).
DISCUSSION
The results of this controlled clinical trial indicate
that ampicillin/sulbactam is as safe and effective for
the treatment of PID as cefoxitin. These findings
are consistent with those from a number of other
studies comparing ampicillin/sulbactam with either
TABLE 4. Most common clinical and laboratory
adverse events (%)
Ampicillin/sulbactam Cefoxitin
(N 47) (N 46)
Clinical
Vaginal yeast infection 28 17
Constipation II 7
Nausea/vomiting 4 II
Abdominal pain 2 2
Itching at injection site 2 2
Headache 2 2
Diarrhea 2 4
Laboratory
Anemia 6 7
Neutropenia 6 4
Eosinophilia 4 0
Elevated SGOT 4 0
this cephamycin or combination therapies for PID.
McGregor et al. 12 compared ampicillin/sulbactam
with cefoxitin plus doxycycline in 103 evaluable
patients with PID and noted no significant differ-
ence in clinical response rates. Hemsell et al.9 com-
pared ampicillin/sulbactam and cefoxitin in 117 pa-
tients with either uncomplicated or complicated
acute PID. In this trial, the significantly greater
efficacy of ampicillin/sulbactam resulted from the
combination’s activity in PID complicated by a pel-
vic inflammatory mass. Duration of therapy was
also shorter for patients with complicated PID
who received ampicillin/sulbactam than for those
treated with cefoxitin. The bacteriologic efficacy of
ampicillin/sulbactam was equivalent to that of ce-
foxitin for eradication of pathogens associated with
PID.1
In comparison with other traditional combina-
tions, ampicillin/sulbactam achieved clinical cure
rates comparable to those with metronidazole plus
gentamicins and clindamycin plus gentamicin6 in
women with PID.
The excellent activity of ampicillin/sulbactam
against N. gonorrhoeae and both gram-positive and
gram-negative aerobes and anaerobes frequently
involved in PID is well documented,9,,2 but like
cefoxitin, ampicillin/sulbactam is less active against
C. trachomatis. Although several investigations have
suggested that [3-1actam antibiotics may be effec-
tive in C. trachomatis infections, 17,8 Kosseim et
al.9 reported that ampicillin/sulbactam appeared to
suppress rather than eradicate this pathogen. The
investigators’ recommendationmadministration of
doxycycline together with ampicillin/sulbactam for
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C. trachomatis-associated PIDmwas adopted in the
present study.
A recent meta-analysis evaluated the effective-
ness of a large number of single-drug and combi-
nation therapies in women with PID.z Ampicillin/
sulbactam, with the addition of doxycycline when
appropriate, had clinical and bacteriologic efficacy
comparable to that of clindamycin plus gentamicin,
tobramycin, or amikacin; metronidazole plus doxy-
cycline; either cefoxitin, cefotetan, or cefotaxime
plus doxycycline; ciprofloxacin or ofloxacin; or the
combination of amoxicillin, clavulanic acid, and
doxycycline. Ampicillin/sulbactam was also less ex-
pensive than most of these regimens, including
those involving cefoxitin,e This last conclusion is
supported by results of a recent pharmacoeconomic
analysis that directly compared the cost-effective-
ness of these two agents. Conversion from cefoxitin
to ampicillin/sulbactam at a university teaching
hospital resulted in an initial annual savings of
$30,000 to $50,000. 21
In summary, PID, a common infection among
sexually active women, may entail a significant risk
of long-term sequelae, including chronic abdomi-
nal pain, ectopic pregnancy, and infertility.22 Ef-
fective treatment of this disease requires broad an-
timicrobial coverage that traditionally has been
achieved with relatively expensive combination
therapy involving administration of as many as
three agents with different dosage schedules.23,24
The combination of the 3-1actam ampicillin with
the [3-1actamase inhibitor sulbactam has demon-
strated excellent clinical and bacteriologic efficacy
in patients with PID, and is less expensive than
many other therapies, including cefoxitin.
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